Cargando…

Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients

Cell line studies demonstrate that the PI3K/Akt pathway is upregulated in hormone-refractory prostate cancer (HRPC) and can result in phosphorylation of the androgen receptor (AR). The current study therefore aims to establish if this has relevance to the development of clinical HRPC. Immunohistoche...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCall, P, Gemmell, L K, Mukherjee, R, Bartlett, J M S, Edwards, J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2275485/ https://www.ncbi.nlm.nih.gov/pubmed/18349820 http://dx.doi.org/10.1038/sj.bjc.6604152

Ejemplares similares

Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients
por: Willder, J M, et al.
Publicado: (2013)

Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer
por: Tam, L, et al.
Publicado: (2007)

Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer
por: Mukherjee, R, et al.
Publicado: (2011)

Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer
por: Edwards, J, et al.
Publicado: (2003)

Is PTEN loss associated with clinical outcome measures in human prostate cancer?
por: McCall, P, et al.
Publicado: (2008)

Effects of platelet-activating factor and its differential regulation by androgens and steroid hormones in prostate cancers
por: Xu, B, et al.
Publicado: (2013)

Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells
por: Terakawa, T, et al.
Publicado: (2009)

Secreted Frizzled-related protein-1 is a negative regulator of androgen receptor activity in prostate cancer
por: Kawano, Y, et al.
Publicado: (2009)

miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients
por: Hagman, Z, et al.
Publicado: (2013)

Insulin-like growth factor binding protein-6 inhibits prostate cancer cell proliferation: implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer
por: Koike, H, et al.
Publicado: (2005)

NFκB signalling is upregulated in a subset of castrate-resistant prostate cancer patients and correlates with disease progression
por: McCall, P, et al.
Publicado: (2012)

Phosphorylation of eIF4E serine 209 is associated with tumour progression and reduced survival in malignant melanoma
por: Carter, Julia H, et al.
Publicado: (2016)

Androgen receptors are acquired by healthy postmenopausal endometrial epithelium and their subsequent loss in endometrial cancer is associated with poor survival
por: Kamal, A M, et al.
Publicado: (2016)

Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer
por: Armstrong, K, et al.
Publicado: (2011)

Phosphorylation of the Androgen Receptor by PIM1 in Hormone Refractory Prostate Cancer
por: Ha, Susan, et al.
Publicado: (2012)

The interaction between androgen receptor and semenogelin I: a synthetic LxxLL peptide antagonist inhibits the growth of prostate cancer cells
por: Li, Peng, et al.
Publicado: (2018)

Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction
por: Lee, G T, et al.
Publicado: (2014)

TGFβ-induced phosphorylation of Par6 promotes migration and invasion in prostate cancer cells
por: Mu, Y, et al.
Publicado: (2015)

Androgen-related expression of G-proteins in ovarian cancer
por: Sheach, L A, et al.
Publicado: (2009)

Luteinising hormone-releasing hormone analogue reverses the cell adhesion profile of EGFR overexpressing DU-145 human prostate carcinoma subline
por: Yates, C, et al.
Publicado: (2005)

Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer
por: Rao, S R, et al.
Publicado: (2017)

The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells
por: Henderson, D J P, et al.
Publicado: (2014)

Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer
por: Dudderidge, T J, et al.
Publicado: (2007)

The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone
por: Campbell, Esther J, et al.
Publicado: (2016)

Intracrine androgen biosynthesis in renal cell carcinoma
por: Lee, Geun Taek, et al.
Publicado: (2017)

Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues
por: Riddick, A C P, et al.
Publicado: (2005)

Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress
por: Whitaker, H C, et al.
Publicado: (2013)

Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology
por: Ursin, G, et al.
Publicado: (2005)

Androgen Receptor Phosphorylation at Serine 308 and Serine 791 Predicts Enhanced Survival in Castrate Resistant Prostate Cancer Patients
por: McCall, Pamela, et al.
Publicado: (2013)

Expression of phosphorylated eIF4E-binding protein 1, but not of eIF4E itself, predicts survival in male breast cancer
por: Millican-Slater, Rebecca A, et al.
Publicado: (2016)

Slow proliferation as a biological feature of colorectal cancer metastasis
por: Anjomshoaa, A, et al.
Publicado: (2009)

Prognostic value of protein tyrosine kinase 6 (PTK6) for long-term survival of breast cancer patients
por: Aubele, M, et al.
Publicado: (2008)

Tamoxifen resistance in early breast cancer: statistical modelling of tissue markers to improve risk prediction
por: Baneshi, M R, et al.
Publicado: (2010)

PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas
por: Aubele, M, et al.
Publicado: (2007)

Specificity and heregulin regulation of Ebp1 (ErbB3 binding protein 1) mediated repression of androgen receptor signalling
por: Zhang, Y, et al.
Publicado: (2005)

Proline-rich tyrosine kinase 2 and its phosphorylated form pY881 are novel prognostic markers for non-small-cell lung cancer progression and patients' overall survival
por: Kuang, B-H, et al.
Publicado: (2013)

The relationship between tumour budding, the tumour microenvironment and survival in patients with invasive ductal breast cancer
por: Gujam, F J A, et al.
Publicado: (2015)

Elevated tumour interleukin-1β is associated with systemic inflammation: a marker of reduced survival in gastro-oesophageal cancer
por: Deans, D A C, et al.
Publicado: (2006)

Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials
por: Som, A, et al.
Publicado: (2012)

Chronic bacterial inflammation induces prostatic intraepithelial neoplasia in mouse prostate
por: Elkahwaji, J E, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_k78n4ug3sk2cttbskdes0e9ihb